{"id":954090,"date":"2026-04-23T07:34:53","date_gmt":"2026-04-23T11:34:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/"},"modified":"2026-04-23T07:34:53","modified_gmt":"2026-04-23T11:34:53","slug":"corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/","title":{"rendered":"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., April  23, 2026  (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company\u2019s Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology.<\/p>\n<p>\u201cThe addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for ITK inhibition and immune modulation across immune and inflammatory diseases and cancer,\u201d said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. \u201cDr. Chan has deep expertise in immunology exemplified by a remarkable record of achievement across academia and industry, including having led major discoveries in T cell signaling and their related applications to the treatment of immune diseases and cancer. We welcome Dr. Chan to the Corvus Board of Directors and look forward to his contributions as we continue developing soquelitinib and our ITK inhibition platform.\u201d<\/p>\n<p>\u201cBased on the scientific and clinical data produced to date, I believe that ITK inhibition with soquelitinib represents an important new mechanism to modulate or reset the immune system, providing potential to treat a wide range of diseases across many areas of medicine,\u201d commented Dr. Chan. \u201cI am eager to bring my experience in research and drug development to Corvus as we advance ITK inhibitors to help improve outcomes for patients.\u201d<\/p>\n<p>Dr. Chan joined Genentech in 2001 and most recently served as Senior Vice President, Research Biology from 2010-2025. Prior to this, he held roles of increasing responsibility focused on immunology and antibody engineering. Dr. Chan currently serves as an Associate Adjunct Professor of Medicine in the Division of Rheumatology at University of California, San Francisco (UCSF), a position he has held since 2020. He joined UCSF in 2004 as an Associate Clinical Professor of Medicine in the Division Rheumatology, after previously serving as an Assistant Adjunct Professor in the Division from 1992-1993. From 1994 to 2001, Dr. Chan served as Associate Professor of Medicine at Washington University School of Medicine, where he was appointed as a member of the Howard Hughes Medical Institute.<\/p>\n<p>Dr. Chan received B.A. and M.S. degrees in Chemistry from Northwestern University and M.D. and Ph.D. degrees from Washington University School of Medicine. He completed his internal medicine residency at Barnes Hospital, Washington University School of Medicine and clinical fellowship in rheumatology at UCSF. During his career, he served as an attending physician at UCSF Long-Moffitt Hospital and Barnes Hospital.<\/p>\n<p>\n        <strong>About\u00a0Corvus Pharmaceuticals<\/strong><br \/>\n        <br \/>Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed\/refractory PTCL and in a Phase 2 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EmhyIvHKo7VhXKGYvSi3uZJeKPqzFUxQfLKygW3bZN1W4gfQnvcv62ycCgmnUs3R-3q-JhJu2U_YZR31Tep9JtT-eNcxbpZ3NWDS2ElT-_o=\" rel=\"nofollow\" target=\"_blank\">www.corvuspharma.com<\/a>\u00a0or follow the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r6s2Rra2ClhhQOWmSxyGYRAoumStIxgHyqyJ3CLy1yFI4b5R8IkbZUF6-Jrqdn_bbGQ8D1eoig6Qd3ISFZdSrzxgPkA9sHpbyTrQiaWwmDOo7IFJTfA0MlDN-XOG4Zlb\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements, including statements related to the potential safety and efficacy of the Company\u2019s product candidates; the potential use of soquelitinib to treat a variety of hematological cancers and autoimmune diseases; the Company\u2019s leadership position; clinical strategy and the design of clinical trials, including the timeline for initiation, target or expected number of patients to be enrolled, dose levels, number of sites and other product development milestones; and the amount of cash to fund operations into the second quarter of 2028, and Dr. Chan\u2019s expected contributions to the Company\u2019s board of directors. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cwill,\u201d \u201cmay\u201d or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company\u2019s control. The Company\u2019s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 12, 2026, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company\u2019s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company\u2019s estimates relating to its ability to initiate and\/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company\u2019s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; the Company\u2019s ability to accurately estimate the cash on hand providing funding into the second quarter of 2028 and the Company\u2019s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The Company\u2019s results for the fourth quarter and year ended December 31, 2025 are not necessarily indicative of its operating results for any future periods.<\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Leiv Lea<br \/>Chief Financial Officer<br \/>Corvus Pharmaceuticals, Inc.<br \/>+1-650-900-4522<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2kpPPXsJlebGX2wXuxtmOTY6hiNa3jOfwOEBvRV8GoXRf66l5jlTh3pzRurIaAFHTjq7Q9y0m3O_YdKZe9mi6X8vL_IDFCD9wsqTOz1E0ac=\" rel=\"nofollow\" target=\"_blank\">llea@corvuspharma.com<\/a><\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Julia Stern<br \/>Real Chemistry<br \/>+1-763-350-5223<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=navyR4vIl_m8dk2LdwcdvgFZuJ8LClEsqKtVsJLyrPSKKI_d0FbSWTDKnN_plhFODAE4AibgtzCKOWgbbO7M3ZZSmXzJkajv5XYfeN_JjqBGA-n7zPDpVP6Yr1f1Z5QI\" rel=\"nofollow\" target=\"_blank\">jstern@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTIwNDQ0MzMtOWVkYi00NmY4LWJiOGMtYjA0OTQ2M2M1YWM4LTEwMzc1NjUtMjAyNi0wNC0yMy1lbg==\/tiny\/Corvus-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company\u2019s Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology. \u201cThe addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for ITK inhibition and immune modulation across immune and inflammatory diseases and cancer,\u201d said Richard A. Miller, M.D., co-founder, president and chief &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954090","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company\u2019s Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology. \u201cThe addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for ITK inhibition and immune modulation across immune and inflammatory diseases and cancer,\u201d said Richard A. Miller, M.D., co-founder, president and chief &hellip; Continue reading &quot;Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T11:34:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors\",\"datePublished\":\"2026-04-23T11:34:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/\"},\"wordCount\":1093,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/\",\"name\":\"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=\",\"datePublished\":\"2026-04-23T11:34:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company\u2019s Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology. \u201cThe addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for ITK inhibition and immune modulation across immune and inflammatory diseases and cancer,\u201d said Richard A. Miller, M.D., co-founder, president and chief &hellip; Continue reading \"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-23T11:34:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors","datePublished":"2026-04-23T11:34:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/"},"wordCount":1093,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/","name":"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=","datePublished":"2026-04-23T11:34:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTUwOCM3NTUwOTI4IzIwMjU5OTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954090"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954090\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}